Literature DB >> 17333138

Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol.

A A Boucher1, J C Arnold, L Duffy, P R Schofield, J Micheau, T Karl.   

Abstract

RATIONALE: Cannabis use may precipitate schizophrenia especially if the individual has a genetic vulnerability to this mental disorder. Human and animal research indicates that neuregulin 1 (Nrg1) is a susceptibility gene for schizophrenia.
OBJECTIVES: The aim of this study was to investigate whether dysfunction in the Nrg1 gene modulates the behavioural effects of Delta(9)-tetrahydrocannabinol (THC), the major psychotropic component of cannabis.
MATERIALS AND METHODS: Heterozygous Nrg1 transmembrane-domain knockout mice (Nrg1 HET) were treated with acute THC (0, 5 or 10 mg/kg i.p.) 30 min before being tested using open field (OF), hole board (HB), light-dark (LD), elevated plus maze (EPM), social interaction (SI) and prepulse inhibition (PPI) tests.
RESULTS: Nrg1 HET mice showed differences in baseline behaviour with regard to locomotor activity, exploration and anxiety. More importantly, they were more sensitive to the locomotor suppressant actions of THC compared to wild type-like (WT) mice. In addition, Nrg1 HET mice expressed a greater THC-induced enhancement in % PPI than WT mice. The effects of THC on anxiety-related behaviour were task-dependent, with Nrg1 HET mice being more susceptible than WT mice to the anxiogenic effects of THC in LD, but not in the EPM, SI and OF tests.
CONCLUSIONS: Nrg1 HET mice were more sensitive to the acute effects of THC in an array of different behaviours including those that model symptoms of schizophrenia. It appears that variation in the schizophrenia-related neuregulin 1 gene alters the sensitivity to the behavioural effects of cannabinoids.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17333138     DOI: 10.1007/s00213-007-0721-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.415


  100 in total

Review 1.  Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics.

Authors:  A G Cardno; I I Gottesman
Journal:  Am J Med Genet       Date:  2000

Review 2.  Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests.

Authors:  J N Crawley
Journal:  Brain Res       Date:  1999-07-17       Impact factor: 3.252

Review 3.  Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review.

Authors:  M A Geyer; K Krebs-Thomson; D L Braff; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

4.  Comorbid anxiety disorders and divalproex sodium use among partial hospital patients with psychotic disorders.

Authors:  Mark H Townsend; Michael S Wilson
Journal:  Compr Psychiatry       Date:  2005 Sep-Oct       Impact factor: 3.735

5.  Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine.

Authors:  J C Arnold; A N Topple; G E Hunt; I S McGregor
Journal:  Eur J Pharmacol       Date:  1998-07-31       Impact factor: 4.432

6.  Resocialisation of isolation-reared rats does not alter their anxiogenic profile on the elevated X-maze model of anxiety.

Authors:  I K Wright; N Upton; C A Marsden
Journal:  Physiol Behav       Date:  1991-12

7.  Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice.

Authors:  R J Rodgers; J K Shepherd
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats.

Authors:  J B Acri; D E Morse; E J Popke; N E Grunberg
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

9.  Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat.

Authors:  R S Mansbach; M A Geyer
Journal:  Neuropsychopharmacology       Date:  1989-12       Impact factor: 7.853

10.  Two cases of "cannabis acute psychosis" following the administration of oral cannabis.

Authors:  Bernard Favrat; Annick Ménétrey; Marc Augsburger; Laura E Rothuizen; Monique Appenzeller; Thierry Buclin; Marie Pin; Patrice Mangin; Christian Giroud
Journal:  BMC Psychiatry       Date:  2005-04-01       Impact factor: 3.630

View more
  51 in total

Review 1.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

2.  Disruption of the neuregulin 1 gene in the rat alters HPA axis activity and behavioral responses to environmental stimuli.

Authors:  S B Taylor; A R Taylor; J A Markham; A M Geurts; B Z Kanaskie; J I Koenig
Journal:  Physiol Behav       Date:  2010-11-16

3.  Animal models of gene-environment interactions in schizophrenia.

Authors:  Yavuz Ayhan; Akira Sawa; Christopher A Ross; Mikhail V Pletnikov
Journal:  Behav Brain Res       Date:  2009-04-18       Impact factor: 3.332

Review 4.  Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Authors:  Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams
Journal:  Neurosci Biobehav Rev       Date:  2016-09-14       Impact factor: 8.989

Review 5.  The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders.

Authors:  Ismael Galve-Roperh; Javier Palazuelos; Tania Aguado; Manuel Guzmán
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-09       Impact factor: 5.270

Review 6.  Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome.

Authors:  Didier Jutras-Aswad; Jennifer A DiNieri; Tibor Harkany; Yasmin L Hurd
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-02       Impact factor: 5.270

7.  Neuregulin-1 impairs the long-term depression of hippocampal inhibitory synapses by facilitating the degradation of endocannabinoid 2-AG.

Authors:  Huizhi Du; In-Kiu Kwon; Jimok Kim
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

Review 8.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

Review 9.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

Review 10.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.